Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Spirapril. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE known ✓ | P12821 | 15/20 | 0.83 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.98 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Spirapril SCHEMBL11052621 | 1.00 | ABCB11 (0.98) | ABCB11ACELMNASMN1; SMN2PDE3A | |
| Spirapril SCHEMBL7340600 | 1.00 | ABCB11 (0.98) | ABCB11ACELMNASMN1; SMN2PDE3A | |
| Spirapril SCHEMBL7338593 | 1.00 | ABCB11 (0.98) | ABCB11ACELMNASMN1; SMN2PDE3A | |
| Spirapril SCHEMBL7338589 | 1.00 | ABCB11 (0.98) | ABCB11ACELMNASMN1; SMN2PDE3A | |
| Spirapril SCHEMBL6506406 | 1.00 | ABCB11 (0.98) | ABCB11ACELMNASMN1; SMN2PDE3A | |
| Spirapril SCHEMBL11052614 | 1.00 | ABCB11 (0.98) | ABCB11ACELMNASMN1; SMN2PDE3A | |
| Spirapril SCHEMBL3785516 | 1.00 | ABCB11 (0.98) | ABCB11ACELMNASMN1; SMN2PDE3A | |
| Spirapril SCHEMBL17202 | 1.00 | ABCB11 (0.98) | ABCB11ACELMNASMN1; SMN2PDE3A | |
| Spirapril SCHEMBL387353 | 0.99 | ABCB11 (1.00) | ABCB11ACELMNASMN1; SMN2PDE3A | |
| Spirapril SCHEMBL14660503 | 0.99 | ABCB11 (1.00) | ABCB11ACELMNASMN1; SMN2PDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260000653-A1 | TREATMENT OF CNS DISEASES WITH sGC STIMULATORS | TISENTO THERAPEUTICS INC (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250326761-A1 | sGC STIMULATORS | TISENTO THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| US-12435080-B2 | sGC stimulators | TISENTO THERAPEUTICS INC. (US) | 2025-10-07 | — | — | US | disclosed |
| US-20250243205-A1 | sGC STIMULATORS | TISENTO THERAPEUTICS INC (US) | 2025-07-31 | — | — | US | disclosed |
| US-20250115611-A1 | CRYSTALLINE FORMS OF 8-(2-FLUOROBENZYL)-6-(3-(TRIFLUOROMETHYL)-1H-1,2,4-TRIAZOL-5-YL)IMIDAZO[1,2-a]PYRAZINE AS sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2025-04-10 | — | — | US | disclosed |
| US-20250108040-A1 | TREATMENT OF CNS DISEASES WITH sGC STIMULATORS | TISENTO THERAPEUTICS INC (US) | 2025-04-03 | — | — | US | disclosed |
| US-20250059197-A1 | sGC STIMULATORS | TISENTO THERAPEUTICS INC (US) | 2025-02-20 | — | — | US | disclosed |
| US-12220414-B2 | Use of sGC stimulators for the treatment of mitochondrial disorders | TISENTO THERAPEUTICS INC. (US) | 2025-02-11 | — | — | US | disclosed |
| US-12122782-B2 | Crystalline forms of 8-(2-fluorobenzyl)-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyrazine as sGC stimulators | TISENTO THERAPEUTICS INC. (US) | 2024-10-22 | — | — | US | disclosed |
| US-20240342187-A1 | USE OF NEP INHIBITORS FOR THE TREATMENT OF GASTROINTESTINAL SPHINCTER DISORDERS | CURTAILS LLC (US) | 2024-10-17 | — | — | US | disclosed |
| US-11690828-B2 | Treatment of CNS diseases with sGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-20230095799-A1 | CRYSTALLINE FORMS OF AN sGC STIMULATOR | TISENTO THERAPEUTICS INC. | 2023-03-30 | — | — | US | disclosed |
| WO-2023018795-A1 | NEP INHIBITORS FOR THE TREATMENT OF LAMINITIS | CURTAILS LLC (US) | 2023-02-16 | — | — | WO | disclosed |
| WO-2022265984-A1 | USE OF NEP INHIBITORS FOR THE TREATMENT OF GASTROINTESTINAL SPHINCTER DISORDERS | CURTAILS LLC (US) | 2022-12-22 | — | — | WO | disclosed |
| US-11466015-B2 | Crystalline forms of 8-(2-fluorobenzyl)-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyrazine as sGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2022-10-11 | — | — | US | disclosed |
| US-11357777-B2 | Use of sGC stimulators for the treatment of nonalcoholic steatohepatitis (NASH) | CYCLERION THERAPEUTICS, INC. (US) | 2022-06-14 | — | — | US | disclosed |
| EP-3411026-B1 | USE OF STIMULATORS OF SOLUBLE GUANYLATE CYCLASE FOR THE TREATMENT OF NONALCOHOLIC STEATOHEPATITIS (NASH) | CYCLERION THERAPEUTICS INC (US) | 2022-03-09 | — | — | EP | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| WO-2009127251-A1 | COMBINATIONS COMPRISING A RENIN INHIBITOR | NOVARTIS AG (CH) | 2009-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12220414-B2 | Use of sGC stimulators for the treatment of mitochondrial disorders | CS, COQ8A, GLS | ACE 4461/4885ABCB11 3434/4885LMNA 2900/4885 |
| US-11690828-B2 | Treatment of CNS diseases with sGC stimulators | GUCY1A2, GUCY1B2, PDE2A | ACE 4451/4885ABCB11 3436/4885LMNA 4287/4885 |
| US-20250059197-A1 | sGC STIMULATORS | GMPS, GUCY1A2, PDE2A | ACE 3603/4885ABCB11 2663/4885LMNA 3247/4885 |
| US-20250326761-A1 | sGC STIMULATORS | GUCY1A2, PRKG1, GMPS | ACE 4204/4885ABCB11 3848/4885LMNA 3091/4885 |
| US-12435080-B2 | sGC stimulators | GUCY1A2, PRKG1, PDE2A | ACE 3734/4885ABCB11 3818/4885LMNA 3153/4885 |
| US-12122782-B2 | Crystalline forms of 8-(2-fluorobenzyl)-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyrazine as sGC stimulators | GUCY1A2, GUCY1B2, GUCY1A1 | ACE 2746/4885ABCB11 4442/4885LMNA 1840/4885 |
| US-20230095799-A1 | CRYSTALLINE FORMS OF AN sGC STIMULATOR | GUCY1A2, GUCY1B2, GUCY1A1 | ACE 3249/4885ABCB11 4814/4885LMNA 1880/4885 |
| US-11466015-B2 | Crystalline forms of 8-(2-fluorobenzyl)-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyrazine as sGC stimulators | GUCY1A2, GUCY1B2, GUCY1A1 | ACE 2746/4885ABCB11 4442/4885LMNA 1840/4885 |
| US-20260000653-A1 | TREATMENT OF CNS DISEASES WITH sGC STIMULATORS | PDE9A, PDE2A, GUCY1A2 | ACE 3774/4885ABCB11 1438/4885LMNA 2031/4885 |
| US-11357777-B2 | Use of sGC stimulators for the treatment of nonalcoholic steatohepatitis (NASH) | GLS2, GPR119, PRKG1 | ACE 4472/4885ABCB11 2279/4885LMNA 2863/4885 |
| US-20250115611-A1 | CRYSTALLINE FORMS OF 8-(2-FLUOROBENZYL)-6-(3-(TRIFLUOROMETHYL)-1H-1,2,4-TRIAZOL-5-YL)IMIDAZO[1,2-a]PYRAZINE AS sGC STIMULATORS | GUCY1A2, GUCY1B2, GUCY1A1 | ACE 2746/4885ABCB11 4442/4885LMNA 1840/4885 |
| US-20250243205-A1 | sGC STIMULATORS | GMPS, GUCY1A2, PDE2A | ACE 3603/4885ABCB11 2663/4885LMNA 3247/4885 |
| US-20250108040-A1 | TREATMENT OF CNS DISEASES WITH sGC STIMULATORS | GUCY1A2, GUCY1B2, PDE2A | ACE 4451/4885ABCB11 3436/4885LMNA 4287/4885 |
| US-20240342187-A1 | USE OF NEP INHIBITORS FOR THE TREATMENT OF GASTROINTESTINAL SPHINCTER DISORDERS | MME, REN, ACE | ACE 3/4885ABCB11 354/4885LMNA 608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.